DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Defense Health Agency Contracting Activity - DHACA · HT942526ALSRPCOBA · Deadline: September 30, 2026

This listing sits under an agency-wide umbrella (CFDA 12.420, Military Medical Research and Development — ~1078 awards/yr across many separate competitions). Program-level statistics would describe the whole umbrella, not this competition, so we don't show them as if they were this opportunity's history. Any tool showing "award history" for this listing at the program level is describing the umbrella.

Listing summary

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clini…

Eligibility: Unrestricted · Categories: Science and Technology · official listing ↗

This is the free preview

The full brief adds winner tables, recipient breakdowns, the printable "prepared for your client" version, and CSV export — plus a matched-grants list for your client's profile. Client Packet $79 or Pro subscription →

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.